The economic burden of biological therapy in rheumatoid arthritis in clinical practice: Cost-effectiveness analysis of sub-cutaneous anti-TNFα treatment in italian patients

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 4, 2009, Pages 1147-1152

  Benucci, M ^a   Li Gobbi, F ^a   Sabadini, L ^b   Saviola, G ^c   Baiardi, P ^c   Manfredi, M ^a  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

^c IRCCS   (Italy)

Author keywords

Cost effectiveness; TNF blocking agents (adalimumab etanercept)

Indexed keywords

ADALIMUMAB; ETANERCEPT; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL PRACTICE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

EID: 76349114264     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200434     Document Type: Article

References (20)

1. Salaffi F, De Angelis R, Grassi W; MArche Pain Prevalence; Investigation Group (MAPPING) study Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 2005; 23:819-28.
2. Leardini G, Salaffi F, Montanelli R, Gerzeli S, Canesi B. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol 2002; 20:505-15.
3. Kobelt G, Johnsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis. A Two-country model to estimate costs and consequences RA. Arthritis Rheum 2002; 46:2310-19.
4. Fries J, Spitz P, Kraines R, Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23:137-45.
5. Torrance G. Measurement of health state utilities for economic appraisal. A review. J Health Econom 1986; 5:1-30.
6. Kobelt G, Eberhardt K, Geborek P. TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004; 63:4-10.
7. Bansback NJ, Brennan A, Ghatnekar O. Cost-effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005; 64:995-1002.
8. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J.Rheumatol 2002; 29:1156-65.
9. Merkesdal S, Ruof J, Mittendorf T, Zeidler H. Cost-effectiveness of anti-TNF alpha blocking agents in the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2004; 5:1881-6.
10. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Cost of care for patients with rheumatoid arthritis receiving TNF antagonist therapy using claims data. Curr Med Res Opin 2007; 8:1749-59.
11. Walsh CA, Minnock P, Slattery C, Kennedy N, Pang F, Veale DJ. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology 2007; 46:1148-52.
12. Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol 2009; 36:16-25.
13. Kievit W, Adang EM, Fransen J, Kuper HH, van de Lear MA, Jansen TL. The cost- effectiveness and medication cost of three anti-tumor necrosis factor-α agents in treatment of rheumatoid arthritis for prospective clinical practice data. Ann Rheum Dis 2008; 67:1229-34.
14. Gilbert TD, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004; 5:36.
15. Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M. A cost-cost comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001; 19:1051-64.
16. Bullano MF, MvNeeley BJ, Yu UF, Quimbo R, Burawski LP, Yu EB, Woolley JB. Comparison of cost associated with use of etanercept, infliximab, and adalimumab for treatment of rheumatoid arthritis. Manag Care Interface 2006; 19:47-53.
17. Chen YF, Jabanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A. A systemic review of the effectiveness of adalimumab, etanercept and infliximab for treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10:1-229.
18. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: cost and outcomes in follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004; 63:4-10.
19. Rubio Terres C, Ordovas Baines JP, Pla Poblator R, Marrtinez Nieto C, Sanchez Garre MJ, Rosado Souviron MA. Use and cost of biological disease modifing anti-rheumatic drugs in Spain (PRAXIS Study). Farm Hosp 2007; 31:78-92.
20. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost-effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005; 64:1174-9.